361 related articles for article (PubMed ID: 37153738)
1. Bench-to-bedside development of multifunctional flexible embolic agents.
Wang D; Rao W
Theranostics; 2023; 13(7):2114-2139. PubMed ID: 37153738
[TBL] [Abstract][Full Text] [Related]
2. Multifunctional microbeads for drug delivery in TACE.
Bannerman D; Wan W
Expert Opin Drug Deliv; 2016 Sep; 13(9):1289-300. PubMed ID: 27223469
[TBL] [Abstract][Full Text] [Related]
3. Drug delivery in transarterial chemoembolization of hepatocellular carcinoma: Ex vivo evaluation using transparent tissue imaging.
Hong S; Choi WS; Purushothaman B; Koh J; Kim HC; Chung JW; Song JM; Choi JW
Acta Biomater; 2022 Dec; 154():523-535. PubMed ID: 36374750
[TBL] [Abstract][Full Text] [Related]
4. Cirrhotic hepatocellular carcinoma-based decellularized liver cancer model for local chemoembolization evaluation.
Wang M; Gao Y; Liu X; Li Z; Xiao J; Gao X; Gibson MI; Guo Q
Acta Biomater; 2024 Mar; 176():144-155. PubMed ID: 38244660
[TBL] [Abstract][Full Text] [Related]
5. Current trends in the treatment of hepatocellular carcinoma with transarterial embolization: a cross-sectional survey of techniques.
Young S; Craig P; Golzarian J
Eur Radiol; 2019 Jun; 29(6):3287-3295. PubMed ID: 30350163
[TBL] [Abstract][Full Text] [Related]
6. Short-term efficacy and safety of callispheres drug-loaded microsphere embolization in primary hepatocellular carcinoma.
Li J; Wang N; Shi C; Liu Q; Song J; Ye X
J Cancer Res Ther; 2021 Jul; 17(3):733-739. PubMed ID: 34269307
[TBL] [Abstract][Full Text] [Related]
7. Transarterial chemoembolization for unresectable hepatocellular carcinoma: A comparison of the efficacy and safety of 2 embolic agents.
Chen S; Yu W; Zhang K; Liu W; Chen Q
Medicine (Baltimore); 2018 May; 97(21):e10832. PubMed ID: 29794774
[TBL] [Abstract][Full Text] [Related]
8. Drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma: Current state of the art.
Facciorusso A
World J Gastroenterol; 2018 Jan; 24(2):161-169. PubMed ID: 29375202
[TBL] [Abstract][Full Text] [Related]
9. Transarterial radioembolization versus chemoembolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial.
Seinstra BA; Defreyne L; Lambert B; Lam MG; Verkooijen HM; van Erpecum KJ; van Hoek B; van Erkel AR; Coenraad MJ; Al Younis I; van Vlierberghe H; van den Bosch MA
Trials; 2012 Aug; 13():144. PubMed ID: 22913492
[TBL] [Abstract][Full Text] [Related]
10. Transarterial chemoembolization (TACE) in the management of hepatocellular carcinoma: Results of a French national survey on current practices.
Fohlen A; Tasu JP; Kobeiter H; Bartoli JM; Pelage JP; Guiu B
Diagn Interv Imaging; 2018 Sep; 99(9):527-535. PubMed ID: 29609903
[TBL] [Abstract][Full Text] [Related]
11. Sulfamethazine-based pH-sensitive hydrogels with potential application for transcatheter arterial chemoembolization therapy.
Lym JS; Nguyen QV; Ahn da W; Huynh CT; Jae HJ; Kim YI; Lee DS
Acta Biomater; 2016 Sep; 41():253-63. PubMed ID: 27184404
[TBL] [Abstract][Full Text] [Related]
12. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma.
Kloeckner R; Weinmann A; Prinz F; Pinto dos Santos D; Ruckes C; Dueber C; Pitton MB
BMC Cancer; 2015 Jun; 15():465. PubMed ID: 26059447
[TBL] [Abstract][Full Text] [Related]
13. Current status of embolic agents for liver tumor embolization.
Osuga K; Maeda N; Higashihara H; Hori S; Nakazawa T; Tanaka K; Nakamura M; Kishimoto K; Ono Y; Tomiyama N
Int J Clin Oncol; 2012 Aug; 17(4):306-15. PubMed ID: 22806426
[TBL] [Abstract][Full Text] [Related]
14. Update on Transarterial Chemoembolization with Drug-Eluting Microspheres for Hepatocellular Carcinoma.
Nouri YM; Kim JH; Yoon HK; Ko HK; Shin JH; Gwon DI
Korean J Radiol; 2019 Jan; 20(1):34-49. PubMed ID: 30627020
[TBL] [Abstract][Full Text] [Related]
15. Treatment efficacy and safety of drug-eluting beads transarterial chemoembolization versus conventional transarterial chemoembolization in hepatocellular carcinoma patients with arterioportal fistula.
Cai L; Li H; Guo J; Zhao W; Duan Y; Hou X; Cheng L; Du H; Shao X; Diao Z; Hao Y; Zheng X; Li C; Li W
Cancer Biol Ther; 2022 Dec; 23(1):89-95. PubMed ID: 35230928
[TBL] [Abstract][Full Text] [Related]
16. Recent advances and applications of microspheres and nanoparticles in transarterial chemoembolization for hepatocellular carcinoma.
Jia G; Van Valkenburgh J; Chen AZ; Chen Q; Li J; Zuo C; Chen K
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2022 Mar; 14(2):e1749. PubMed ID: 34405552
[TBL] [Abstract][Full Text] [Related]
17. Drug-eluting bead transarterial chemoembolization (TACE) exhibits superior efficacy and equal tolerance to conventional TACE in hepatocellular carcinoma patients with conventional TACE history.
Tang J; Huang Z; Xu J; Lv Q; Wang P
Clin Res Hepatol Gastroenterol; 2022 Mar; 46(3):101814. PubMed ID: 34597848
[TBL] [Abstract][Full Text] [Related]
18. Impact of particle size of multivesicular liposomes on the embolic and therapeutic effects in rabbit VX2 liver tumor.
Tang H; Cao C; Zhang G; Sun Z
Drug Deliv; 2023 Dec; 30(1):1-16. PubMed ID: 36644796
[TBL] [Abstract][Full Text] [Related]
19. LncRNA H19 modulated by miR-146b-3p/miR-1539-mediated allelic regulation in transarterial chemoembolization of hepatocellular carcinoma.
Song Y; Xing H; Zhou L; Zhang N; Yang M
Arch Toxicol; 2021 Sep; 95(9):3063-3070. PubMed ID: 34251499
[TBL] [Abstract][Full Text] [Related]
20. Conventional transarterial chemoembolization vs microsphere embolization in hepatocellular carcinoma: a meta-analysis.
Ni JY; Xu LF; Wang WD; Sun HL; Chen YT
World J Gastroenterol; 2014 Dec; 20(45):17206-17. PubMed ID: 25493037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
